Prognostic Value of Adipokine Levels of Patients With Chronic Heart Failure

Completed

• Conditions: Chronic Heart Failure

• Registration Number: NCT02812797
• Lead Sponsor: Chongqing Medical University

Brief Summary

The purpose of this study is to determine whether expressions of adipokines can provide prognostic information concerning patients with chronic heart failure.

Detailed Description

Not available

Study Timeline

• Study Start: 2016-06
• Study First Submitted: 2016-06-20
• Study First Submitted QC: 2016-06-22
• Study First Posted: 2016-06-24
• Primary Completion: 2019-08
• Study Completion: 2020-01
• Status Verified: 2020-03
• Last Update Submitted: 2020-03-01
• Last Update Posted: 2020-03-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 98

Inclusion Criteria

• Patients who are giving open chest surgical treatment with a history of chronic heart failure (NYHA II ~ IV) more than 6 months.
• Patients from whom informed consent has been properly obtained in writing prior to start of the trial.

Exclusion Criteria

• Patients with concurrent infection or any documented inflammatory illness, such as arthritis or connective tissue diseases,or any other malignancy.
• Patients with a history of cardiomyopathy.
• Patients with Chronic arrhythmia.
• Pregnant women
• Severe hepatic dysfunction or End-stage renal failure.
• Uncontrolled hypertension.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
All-cause mortality	Change from Baseline at 3, 6 and 12 months

Secondary Outcome Measures

Name	Time	Method
Cardiovascular death	Change from Baseline at 3, 6 and 12 months
Cardiac transplantation	Change from Baseline at 3, 6 and 12 months
plasma brain natriuretic peptide (BNP) concentration	Week:4
New York Heart Association (NYHA) Classification	Week:4
re-hospitalization	Change from Baseline at 3, 6 and 12 months	Heart failure with re-hospitalization is documented by at least one of the following: worse exercise tolerance and respiratory distress with NYHA class III or IV symptoms, presence of pulmonary rales, or chest radiography showing pulmonary congestion, which needs an augmented decongestive regimen with oral or intravenous medications during an in-hospital stay.

Trial Locations

Locations (1)

The First Affiliated Hospital of Chongqing Medical University; 🇨🇳 Chongqing, Chongqing, China